Radiosensitizer conjugation to the carcinoma 19-9 monoclonal antibody.
Cancer Res
; 47(15): 4071-5, 1987 Aug 01.
Article
in En
| MEDLINE
| ID: mdl-3496956
ABSTRACT
Misonidazole was covalently conjugated (3-68 mol drug/mol antibody) to 19-9 monoclonal antibody directed against a colorectal carcinoma tumor-associated antigen as a method for targeting radiosensitizing agents. This attachment was accomplished by the mixed anhydride method using the hemisuccinate derivative of misonidazole. Evaluation of conjugates in vitro shows a loss of antibody binding activity with increasing loading levels; however, significant binding activity is retained even at relatively high sensitizer/antibody ratios. This observation was consistent in three binding assays a competitive radioimmunoassay; an enzyme immunoassay; and an affinity column assay. From these studies, it was concluded that the optimal loading factor for misonidazole-antibody conjugates, when it is used for immunochemotherapy lies between 8 and 15. In vitro release studies indicated that conjugates are hydrolytically stable (t1/2 = 4 days) under physiological conditions.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunotoxins
/
Misonidazole
/
Antigens, Neoplasm
Language:
En
Journal:
Cancer Res
Year:
1987
Document type:
Article
Country of publication:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA